Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Advaccine Biotech

Request full access

Developing prophylactic and therapeutic vaccines for global diseases

Dongcheng District, ChinaBiotech & Life Sciences

About Advaccine Biotech

Advaccine Biotech is a clinical-stage biopharmaceutical company founded in 2009 by Dr. Bin Wang, an Emeritus Professor from Fudan University. The company focuses on developing, manufacturing, and commercializing prophylactic and therapeutic vaccines to address infectious diseases, cancer, and autoimmune diseases.

The company's pipeline includes candidates for diseases with significant unmet medical needs, such as Respiratory Syncytial Virus (RSV), Hepatitis B (HBV), and various cancers. One of its most advanced candidates is ADV110, a protein subunit RSV vaccine designed for children and the elderly, which has entered Phase 2 clinical trials. Advaccine utilizes proprietary technology platforms, including novel adjuvants and a cellular immunity assessment platform, to accelerate the development of its vaccine candidates. A key area of focus has been DNA vaccine technology, which offers advantages in stability, storage, and rapid production compared to traditional vaccines.

Advaccine gained prominence through its strategic collaboration with U.S.-based Inovio Pharmaceuticals to co-develop and commercialize a DNA vaccine for COVID-19, INO-4800, in Greater China. This partnership leveraged Advaccine's regional expertise and its large-scale GMP plasmid manufacturing facility in Suzhou, capable of producing over 100 million vaccine doses annually. The business model involves in-house research and development, strategic partnerships for co-development and commercialization, and in-licensing opportunities. Revenue generation is anticipated from product sales upon regulatory approval, milestone payments, and royalties from licensing agreements.

Source: Dealroom company data

At a glance

Headquarters
Dongcheng District, China
Sector
Biotech & Life Sciences

Advaccine Biotech in the Dongcheng District ecosystem

Live from Dealroom

The Advaccine Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Fortune Capital
  • Star Capital

Series B and later2 investors entered at this stage

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Dongcheng District HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Advaccine Biotech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Advaccine Biotech on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.